版本:
中国

BRIEF-Oncoquest announces enrollment of first patient in phase 1/2 clinical study

May 9 Quest Pharmatech Inc:

* Oncoquest announces enrollment of first patient in phase 1/2 clinical study using combination of oregovomab with checkpoint inhibitor nivolumab in recurrent ovarian cancer Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐